Valuation : Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

Market Cap 1.4TCr 208.97Cr 179.38Cr 167.94Cr 153.78Cr 289.68Cr 20TCr 290.5Cr 1.99TCr 777.37Cr 10TCr 784.56Cr 767.61Cr 33TCr P/E 2026 *
18.3x
P/E 2027 * 15.6x
Enterprise Value 1.26TCr 187.73Cr 161.15Cr 150.87Cr 138.15Cr 260.25Cr 18TCr 260.99Cr 1.79TCr 698.39Cr 9.04TCr 704.85Cr 689.63Cr 30TCr EV / Sales 2026 *
2.18x
EV / Sales 2027 * 2.34x
Free-Float
14.33%
Yield 2026 *
0.66%
Yield 2027 * 0.75%
26/05 Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Approves Ordinary Final Dividend on A Shares for the Year Ended December 31, 2025, Payable on 18 June 2026 CI
22/05 Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Announces Board Changes CI
30/04 Shenzhen Hepalink Pharmaceutical's Profit Rises 20% in Q1 MT
29/04 Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
30/03 Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Proposes Final Ordinary Cash Dividend for the Year Ended 31 December 2025, Payable on 22 July 2026 CI
30/03 Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
30/01 Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Provides Earnings Guidance for the Year Ended December 31, 2025 CI
30/01 Shenzhen Hepalink Forecasts Up to 56% Lower Profit in 2025 MT
16/12 Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Approves the Election of Pu Hong as Independent Non-Executive Director, Effective December 16, 2025 CI
24/11 Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Approves Retirement of Chuan Lu from the Board CI
30/25/30 Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025 CI
29/25/29 Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025 CI
18/25/18 Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Completes the First Subject and the First Dosing in the Phase 1 Clinical Trial CI
1 day+3.10%
1 week-1.43%
Current month+6.40%
1 month+10.39%
3 months+2.28%
6 months-15.70%
Current year-12.55%
1 week 9.91
Extreme 9.91
11.57
1 month 9.32
Extreme 9.32
11.57
Current year 8.5
Extreme 8.5
12.64
1 year 8.5
Extreme 8.5
13.46
3 years 6.89
Extreme 6.89
14.34
5 years 6.89
Extreme 6.89
18.89
10 years 6.89
Extreme 6.89
30.69
Manager TitleAgeSince
Chief Executive Officer 65 21/04/1998
Corporate Officer/Principal 61 21/04/1998
Director of Finance/CFO 51 21/08/2023
Director TitleAgeSince
Director/Board Member 61 21/04/1998
Chairman 62 21/04/1998
Director/Board Member 65 21/04/1998
Date Insider Type Main position Quantity % Market Cap.
23/05/23 Sell 11,200 0.0009%
26/05/21 Other

Chief Financial Officer

4,59,588 0.2088%
Change 5-day change 1-year change 3-year change Capi.($)
+3.10%-1.43%-23.46%-6.44% 208.97Cr
-1.12%-5.49%+60.19%+112.43% 1,04800Cr
-1.57%-0.60%+50.33%+59.86% 64TCr
-1.81%-1.41%+24.07%+75.98% 46TCr
-1.17%-2.10%+38.61%+40.43% 36TCr
-2.00%-1.35%+22.22%+38.92% 29TCr
-0.98%+0.53%+2.04%+12.13% 26TCr
-0.76%+0.75%+51.75%+70.45% 24TCr
-3.18%-0.30%-17.23%-53.79% 20TCr
+0.52%+3.78%+30.67%+93.68% 18TCr
Average -0.90%-0.00%+23.92%+44.36% 36.84TCr
Weighted average by Cap. -1.36%-1.46%+38.47%+65.98%

Financials

2026 *2027 *
Net sales 577.55Cr 86Cr 74Cr 69Cr 63Cr 119.12Cr 8.21TCr 119.46Cr 817.74Cr 319.67Cr 4.14TCr 322.62Cr 315.65Cr 14TCr 627.47Cr 93Cr 80Cr 75Cr 69Cr 129.42Cr 8.92TCr 129.78Cr 888.42Cr 347.3Cr 4.49TCr 350.51Cr 342.94Cr 15TCr
Net income 86Cr 13Cr 11Cr 10Cr 9.39Cr 18Cr 1.22TCr 18Cr 121.46Cr 47Cr 614.35Cr 48Cr 47Cr 2.03TCr 100Cr 15Cr 13Cr 12Cr 11Cr 21Cr 1.42TCr 21Cr 141.4Cr 55Cr 715.24Cr 56Cr 55Cr 2.37TCr
Net Debt -142.7Cr -21Cr -18Cr -17Cr -16Cr -29Cr -2.03TCr -30Cr -202.04Cr -79Cr -1.02TCr -80Cr -78Cr -3.38TCr 67Cr 9.93Cr 8.53Cr 7.98Cr 7.31Cr 14Cr 948.84Cr 14Cr 95Cr 37Cr 478.21Cr 37Cr 36Cr 1.58TCr
Logo Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Shenzhen Hepalink Pharmaceutical Group Co Ltd is a China-based company primarily engaged in the heparin industry chain, contract development and manufacturing organization (CDMO) of biological macromolecules, and the investment, development, and commercialization of innovative drugs. The Company operates four segments. The Pharmaceutical Formulations segment manufactures and sells enoxaparin sodium injection and others. The Active Pharmaceutical Ingredients (APIs) segment manufactures and sells standard heparin APIs, enoxaparin APIs and others. The CDMO segment provides process development services for pharmaceutical intermediates and APIs, including process research, optimization, analytical testing, and formulation research. The Other segment engages in other product businesses, such as pancreatic enzymes and casings. The Company conducts its business in the domestic and overseas markets.
Employees
2,150
Date Price Change Volume
27/26/27 CN¥10.60 +1.92% 66,85,978
26/26/26 CN¥10.40 +0.87% 85,45,934
25/26/25 CN¥10.31 +3.10% 96,11,128
24/26/24 CN¥10.00 -4.49% 1,25,12,234
21/26/21 CN¥10.47 -7.18% 2,29,33,199
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
SELL
Number of Analysts
1
Last Close Price
10.60CNY
Average target price
8.500CNY
Spread / Average Target
-19.81%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 002399 Stock